Roxane Labs’ purchase price reduced

The price that Jordanian drug company Hikma Pharmaceuticals is paying for Columbus-based Roxane Laboratories has dropped by $535 million. Hikma said in a regulatory filing today that the cash portion of its deal to buy Roxane from its German owners, Boehringer Ingelheim, has been reduced to $647 million.